Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;19(2):147-53.
doi: 10.1089/cap.2008.053.

The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate

Lawrence Maayan  1 , Natalya Paykina, Jane Fried, Tara Strauss, S Sonia Gugga, Laurence Greenhill
Affiliations

The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate

Lawrence Maayan et al. J Child Adolesc Psychopharmacol. 2009 Apr.

Abstract

Objective: The aim of this study was to assess the effectiveness and tolerability of a long-acting methylphenidate (MPH) formulation, beaded MPH (B-MPH), for treatment of attention-deficit/hyperactivity disorder (ADHD) in 4- and 5-year-old children.

Method: Eleven children (9 boys and 2 girls) with ADHD received 4 weeks of B-MPH treatment in a single-site, open-label pilot study. Medication dosing was flexible, with titration to a maximum of 30 mg/day. A brief education session on behavior management was offered to parents at each treatment visit.

Results: Subjects experienced a mean decrease of 1.09 (standard deviation [SD]=0.73, p<0.01) on the Swanson, Nolan, and Pelham Questionnaire (SNAP-IV) ADHD composite score to an end point of 1.18 (SD=0.64). Subjects demonstrated mean decreases in scores of inattention of 1.01 (SD=0.85, p<0.01) and in hyperactivity/impulsivity of 1.17 (SD=0.74, p<0.01), with end point scores of 1.10 (SD=0.61) and 1.26 (SD=0.77), respectively. The Clinical Global Impressions-Severity (CGI-S) scale showed a statistically significant improvement from a baseline mean of 5 to the final visit mean of 3.36 (p<0.01). At the final visit, the mean daily B-MPH dose was 17.73 mg. Subjects did not experience any statistically significant changes in weight, blood pressure, or pulse during the study. The most common adverse event was decreased appetite.

Conclusion: B-MPH was safe and effective for the treatment of ADHD in the 4- and 5-year-olds participating in this study.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Adverse events.
See this image and copyright information in PMC

References

    1. American Psychiatric Association. Diagnostic, statistical manual of mental disorders. 4th. Washington (DC): American Psychiatric Association; 2000. (DSM-IV-TR)
    1. Conners CK. Attention-deficit/hyperactivity disorder—historical development and overview. J Attention Disord. 2000;3:173–191.
    1. Conners CK. Sitarenios G. Parker JD. Epstein JN. Revision and restandardization of the Conners' Teacher Rating Scale (CTRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998a;26:279–291. - PubMed
    1. Conners CK. Sitarenios G. Parker JD. Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998b;26:257–268. - PubMed
    1. DuPaul GJ. McGoey KE. Eckert TL. VanBrakle J. Preschool children with attention-deficit/hyperactivity disorder: Impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry. 2001;40:508–515. - PubMed

MeSH terms

Substances